BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garin E, Palard X, Rolland Y. Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design. Cancers (Basel) 2020;12:E1557. [PMID: 32545572 DOI: 10.3390/cancers12061557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Salem R, Tselikas L, De Baere T. Interventional treatment of hepatocellular carcinoma. J Hepatol 2022:S0168-8278(22)00229-X. [PMID: 35705428 DOI: 10.1016/j.jhep.2022.03.037] [Reference Citation Analysis]
2 Tibballs J, Clements W. Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment? J Med Imaging Radiat Oncol 2022. [PMID: 35357076 DOI: 10.1111/1754-9485.13405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 d’Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology 2022;29:2422-34. [DOI: 10.3390/curroncol29040196] [Reference Citation Analysis]
4 Canziani L, Marenco M, Cavenaghi G, Manfrinato G, Taglietti A, Girella A, Aprile C, Pepe G, Lodola L. Chemical and Physical Characterisation of Macroaggregated Human Serum Albumin: Strength and Specificity of Bonds with 99mTc and 68Ga. Molecules 2022;27:404. [PMID: 35056719 DOI: 10.3390/molecules27020404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fabritius MP, Ben Khaled N, Kunz WG, Ricke J, Seidensticker M. Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma-Role of Interventional Radiology. J Clin Med 2021;10:5574. [PMID: 34884275 DOI: 10.3390/jcm10235574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 D'Avola D, Granito A, de la Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma. J Hepatol 2021:S0168-8278(21)02185-1. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Bargellini I, Boni G, Traino AC, Bozzi E, Lorenzoni G, Bianchi F, Cervelli R, Depalo T, Crocetti L, Volterrani D, Cioni R. Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT). J Clin Med 2021;10:4315. [PMID: 34640332 DOI: 10.3390/jcm10194315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Fabritius MP, Seidensticker M, Rueckel J, Heinze C, Pech M, Paprottka KJ, Paprottka PM, Topalis J, Bender A, Ricke J, Mittermeier A, Ingrisch M. Bi-Centric Independent Validation of Outcome Prediction after Radioembolization of Primary and Secondary Liver Cancer. J Clin Med 2021;10:3668. [PMID: 34441964 DOI: 10.3390/jcm10163668] [Reference Citation Analysis]
9 Allimant C, Deshayes E, Kafrouni M, Santoro L, de Verbizier D, Fourcade M, Cassinotto C, Hermida M, Guillot C, Mariano-Goulart D, Guiu B. Hepatobiliary Scintigraphy and Glass 90Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver. Diagnostics (Basel) 2021;11:931. [PMID: 34064296 DOI: 10.3390/diagnostics11060931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Vito A, Rathmann S, Mercanti N, El-Sayes N, Mossman K, Valliant J. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Int J Mol Sci 2021;22:4843. [PMID: 34063642 DOI: 10.3390/ijms22094843] [Reference Citation Analysis]
11 Seidensticker M, Fabritius MP, Beller J, Seidensticker R, Todica A, Ilhan H, Pech M, Heinze C, Powerski M, Damm R, Weiss A, Rueckel J, Omari J, Amthauer H, Ricke J. Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization. Cancers (Basel) 2021;13:1992. [PMID: 33919073 DOI: 10.3390/cancers13091992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nodari G, Popoff R, Riedinger JM, Lopez O, Pellegrinelli J, Dygai-Cochet I, Tabouret-Viaud C, Presles B, Chevallier O, Gehin S, Gallet M, Latournerie M, Manfredi S, Loffroy R, Vrigneaud JM, Cochet A. Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy. EJNMMI Res 2021;11:24. [PMID: 33687596 DOI: 10.1186/s13550-021-00766-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Garin E, Tselikas L, Guiu B, Campillo-Gimenez B. Personalised dosimetry for SIRT: new standard or bridge to surgical resection? - Authors' reply. Lancet Gastroenterol Hepatol 2021;6:162. [PMID: 33581755 DOI: 10.1016/S2468-1253(21)00021-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wang P, Xue N, Zhang C, Shan S, Jiang Z, Wu W, Liu X. Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells. Oncol Lett 2021;21:274. [PMID: 33732350 DOI: 10.3892/ol.2021.12535] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in Advanced Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:466-74. [PMID: 33328702 DOI: 10.1055/s-0040-1719187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
16 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]